GlassScriptPhysician profile
Julie B Steele
NPI 1053384461
$91,083.86
in general payments reported to CMS, 2019-2025
9 companies · $11K in 2025
The $11K reported for 2025 was more than what 96% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2021: $9,792 · 2022: $6,036 · 2023: $22K · 2024: $18K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $7,790 · Consulting Fee: $3,598 · Food and Beverage: $1,163 · Honoraria: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,940.00 |
| Travel and Lodging | $7,790.20 |
| Consulting Fee | $3,597.50 |
| Food and Beverage | $1,162.51 |
| Honoraria | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56,812.65 | 2022-2025 | Enhertu |
| Genentech USA, INC. | $24,305.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $9,140.81 | 2019-2023 | Keytruda |
| Abbvie INC. | $450.00 | 2025 | |
| Gen-Probe, INC. | $125.00 | 2025 | Genius Ai Detection |
| Blueprint Medicines Corporation | $122.64 | 2021 | |
| Incyte Corporation | $85.26 | 2024 | Pemazyre |
| Aveo Pharmaceuticals, INC. | $27.47 | 2025 | |
| Dendreon Pharmaceuticals LLC | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.